Keptin-a novel keratinocyte-specific proteinase inhibitor
AssigneeBoard of Regents, The University of Texas System
InventorsKiyoshi Ariizumi, Ponciano D. Cruz
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel keratinocyte-specific secreted protein identified as keptin that inhibits an inflammatory response and activity of proteinase, as well as methods for treating hyperproliferative inflammatory skin diseases using proteinase inhibitor keptin. The invention provides a therapeutic agent for treating psoriasis and squamous cell carcinomas and other inflammatory skin related diseases.
Claims47
An isolated nucleic acid segment encoding a keptin.
A method of expressing a keptin in a cell comprising introducing into the cell an expression vector comprising a nucleic acid segment encoding the keptin and a promoter under conditions that support expression of the keptin.
A method of inhibiting an inflammatory response in a subject comprising providing to the subject an effective amount of a keptin, wherein the keptin inhibits protease activity in keratinocytes.
A method of inhibiting microbial infection in a subject comprising providing to the subject an effective amount of a keptin, wherein the keptin inhibits protease activity in keratinocytes.
A monoclonal antibody that binds immunologically to a keptin.
A hybridoma cell that produces a monoclonal antibody that binds immunologically to a keptin.
A polyclonal antibody preparation, antibodies of which bind immunologically to a keptin.
An oligonucleotide of 10 to 50 bases in length, wherein said oligonucleotide comprises at least 10 consecutive bases from SEQ ID NO:
- 1, SEQ. ID. NO:
- 3, SEQ. ID. NO:
- 5, SEQ. ID. NO:
- 7, SEQ. ID. NO:
- 9, SEQ. ID. NO:
- 11 or SEQ ID NO:
- 13.
A peptide of 10 to 50 residues in length, wherein said peptide comprises at least 10 consecutive residues from SEQ ID NO:
- 2, SEQ. ID. NO:
- 4, SEQ. ID. NO:
- 6, SEQ. ID. NO:
- 8, SEQ. ID. NO:
- 10, SEQ. ID. NO:
- 12 or SEQ ID NO:
- 14.
A method of inhibiting a proteinase comprising contacting to a subject an effective amount of a keptin, wherein the keptin inhibits protease activity in keratinocytes.
A pharmaceutical composition comprising a keptin and a pharmaceutically acceptable buffer, diluent or excipient.
A pharmaceutical composition comprising an expression construct encoding a keptin and a pharmaceutically acceptable buffer, diluent or excipient.
Dependencies are inferred from the claim text.